Clinical trial
Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
NCT00148707 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00148707 |
|---|---|
| Title | Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer |
| Official title | Phase II Study of CT-2103 in Patients With Metastatic Breast Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | CT-2103 (Xyotax) |
| Enrollment | 45 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: